Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetomilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 1.00 |
| ▸ | ECE1 | P42892 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | EIF4E | P06730 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CDC25C | P30307 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetomilast SCHEMBL29369138 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DECE1 | |
| Tetomilast SCHEMBL28295665 | 0.91 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL8924903 | 0.89 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL21653506 | 0.89 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL7499977 | 0.89 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL1545319 | 0.89 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL6197199 | 0.89 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL8924565 | 0.86 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL8923878 | 0.86 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DECE1 | |
| SCHEMBL8923733 | 0.86 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| CN-103622962-A | MMP-2 and/or MMP-9 inhibitor | OTSUKA PHARMA CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-103463084-A | Pharmaceutical preparation compound effective for emphysema caused by MMP-2 and/or MMP-9 | OTSUKA PHARMA CO LTD | 2013-12-25 | — | — | CN | claimed |
| CN-101969949-B | MMP-2 and/or MMP-9 inhibitors | OTSUKA PHARMA CO LTD | 2013-12-25 | — | — | CN | claimed |
| EP-2591806-A1 | Medicinal composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | claimed |
| CN-1813699-B | pharmaceutical composition | OTSUKA PHARMA CO LTD | 2012-04-18 | — | — | CN | claimed |
| EP-2121615-B1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-03-28 | — | — | EP | claimed |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-08-11 | — | — | US | claimed |
| WO-2003009844-A1 | USE OF THIAZOLE DEIRVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-06 | — | — | WO | claimed |
| US-RE37556-E1 | (ALKOXYPHENYL)THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | claimed |
| US-20020013469-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | OTSUKA PHARMACEUTICAL CO., LTD. | 2002-01-31 | — | — | US | claimed |
| US-6291487-B1 | THIAZOLES SUBSTITUTED WITH A PHENYL AND A PYRIDYL GROUP | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | claimed |
| US-6080764-A | PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | claimed |
| EP-0513387-B1 | THIAZOLE DERIVATIVES AS ACTIVE OXYGEN INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2000-03-01 | — | — | EP | claimed |
| EP-0957915-A1 | AGENT FOR INHIBITION OF CYTOKINE PRODUCTION AND AGENT FOR INHIBITION OF CELL ADHESION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-24 | — | — | EP | claimed |
| WO-1998014191-A1 | AGENT FOR INHIBITION OF CYTOKINE PRODUCTION AND AGENT FOR INHIBITION OF CELL ADHESION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-09 | — | — | WO | claimed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | claimed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE4A 1415/4885PDE4B 1380/4885PDE4C 1669/4885 |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | PDE4A 261/4885PDE4B 237/4885PDE4C 361/4885 |
| US-20020013469-A1 | Agent for inhibition of cytokine production and agent for inhibition of cell adhesion | IL2, SELL, IL1RN | PDE4A 3015/4885PDE4B 2706/4885PDE4C 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.